Company intelligence / Profile preview
Hexaell Biotech
Shanghai (Zhangjiang area/Pudong New Area), Shanghai Municipality, Chinahexaell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hexaell Biotech is advancing a bioartificial liver system, HepaCure, based on proprietary hiHeps cell transdifferentiation technology. The IND for HepaCure was cleared by the China NMPA in December 2022, enabling Phase 1/2 clinical trials in patients with acute-on-chronic liver failure. The company focuses on providing alternatives to transplantation for severe liver disease using innovative cell therapy approaches.[5][6] No published late-stage or commercial results yet.
- Therapeutic areas
- Gastroenterology
- Modalities
- Cell therapy (specifically, cell transdifferentiation technology converting fibroblasts to hepatocyte-like cells)Device-drug combination (bioartificial liver system)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Academic collaborations with Chinese Academy of Sciences and other research institutes for core technologies development[9].Funding partnerships with investors such as Lapam Capital, Wu Capital, ZJSTIC, Hengxu Capital, Sherpa Venture Capital,[1] and Shanghai Biomedical Fund.
Beyond the preview
Go deeper on Hexaell Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hexaell Biotech.